Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sierra Oncology, Inc.    SRRA

SIERRA ONCOLOGY, INC.

(SRRA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
06/03/2020 | 05:39pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers

As previously announced, on May 22, 2020, Dr. Nick Glover, the President and Chief Executive Officer of Sierra Oncology, Inc. (the "Company") and member of the Company's Board of Directors (the "Board"), resigned from such roles effective as of the same date (the "Separation Date").

In connection with Dr. Glover's departure, the Company has entered into a separation agreement effective on May 28, 2020 ("Separation Agreement") with Dr. Glover that provides for severance pay in accordance with his employment agreement with the Company in the form of (i) continuation of 12 months of his current base salary to be paid on the Company's normal payroll schedule and (ii) an amount equal to the Company's cost of his group health plan coverage through the earlier of the end of the 12 month severance period or the date he becomes eligible for group health coverage through a new employer, with such pay commencing no later than the first business day following the 60th day following the Separation Date.

Pursuant to the Separation Agreement, Dr. Glover will provide consulting services (the "Consulting Services") to the Company commencing on the Separation Date until the expected end date of December 31, 2020, but which may be terminated at any time by the Company (such period, the "Consulting Period"). During the Consulting Period, Dr. Glover will provide Consulting Services to the Company for up to eight (8) hours per week and in consideration of the performance of the Consulting Services, Dr. Glover will be entitled to receive an hourly rate of $250 CAD, plus GST.

In addition, Dr. Glover's unvested options as of the Separation Date (the "Unvested Options") which but for the termination of his employment, would have vested during the period commencing on the Separation Date and ending on the one-year anniversary date of the Separation Date (the "Termination Options"), will accelerate and vest as at the Separation Date. The vesting date of all Unvested Options other than the Termination Options will accelerate by one year from their original vesting date and following such acceleration will continue to vest in accordance with their new vesting schedule as long as Dr. Glover is performing the Consulting Services. All Unvested Options that remain unvested following the termination of the Consulting Services shall be cancelled as of the termination of such Consulting Services. Furthermore, Dr. Glover will receive an extension of the expiration date of his outstanding stock options, including the Termination Options and any options that vest in connection with the foregoing (the "Vested Options") to 75 days following the Company's announcement, via publicly disseminated press release or a filing with the Securities and Exchange Commission, of the top-line data results from MOMENTUM, its Phase 3 clinical trial of momelotinib for patients with myelofibrosis.

The Separation Agreement includes a general release of claims in favor of the Company. The foregoing description of the Separation Agreement is qualified in its entirety by reference to the text of the Separation Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
Latest news on SIERRA ONCOLOGY, INC.
06/12SIERRA ONCOLOGY : Reports Favorable Long-Term Safety and Dose Intensity Data for..
PR
06/11SIERRA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/03SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/27SIERRA ONCOLOGY : Announces Presentations at Upcoming Investor Conferences
PR
05/26SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/26SIERRA ONCOLOGY : Appoints Dr. Stephen Dilly as President and Chief Executive Of..
PR
05/14SIERRA ONCOLOGY : to Report Favorable Dose Intensity Data and Long-Term Safety D..
PR
05/07SIERRA ONCOLOGY : to Hold KOL Call to Discuss Anemia & Transfusion Dependency as..
PR
05/07SIERRA ONCOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
05/07SIERRA ONCOLOGY, INC. : Results of Operations and Financial Condition, Financial..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -78,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,52x
Yield 2020 -
Capitalization 120 M 120 M -
EV / Sales 2019
Capi. / Sales 2020 -
Nbr of Employees 71
Free-Float 95,9%
Chart SIERRA ONCOLOGY, INC.
Duration : Period :
Sierra Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIERRA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 32,67 $
Last Close Price 11,52 $
Spread / Highest target 317%
Spread / Average Target 184%
Spread / Lowest Target 38,9%
EPS Revisions
Managers
NameTitle
Stephen George Dilly President, Chief Executive Officer & Director
Robert E. Pelzer Chairman
Emma McCann SVP-Operations & Program Management
Sukhi Jagpal Chief Financial Officer
Mark M. Kowalski Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SIERRA ONCOLOGY, INC.-15.89%120
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955